
Biotechnology has figured prominently in recent Medicare coverage and payment zzso Biotech treatments push policy boundaries for several reasons: They attract strong patient zzso they often treat rare or life-threatening diseases; they may have uncertain evidence of health zzso and they are often zzso This paper considers case studies of Medicare coverage for zzso uses of biotech cancer drugs and payments for anemia zzso The cases suggest Medicare's ongoing challenge to balance access considerations, the role and strength of evidence, and cost consequences of new zzso 

